האגודה למלחמה בסרטן - במה - גיליון מס' 23 - מאי 2020

When considering treatment for Stage III or IV BRAF V600mutant+ melanoma

50mg; 75mg

0.5mg; 2mg

Expanding life’s possibilities for the journey ahead

With more than 100,000 1* patients treated worldwide, TAFINLAR + MEKINIST is the first and only approved oral targeted therapy with both 5 year OS data in the metastatic setting and unprecedented data in the adjuvant setting. 2-4 Choose TAFINLAR + MEKINIST for your BRAF V600 mutant patients.

Therapeutic indications Melanoma Dabrafenib/Trametinib as monotherapy or in combination with trametinib/dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. Adjuvant treatment of melanoma Dabrafenib/Trametinib in combination with trametinib/dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib/Trametinib in combination with trametinib/dabrafenib is indicated for the treatment of adult patients with advanced non-small cell

lung cancer with a BRAF V600 mutation. Anaplastic Thyroid Cancer (ATC)

Dabrafenib/Trametinib is indicated, in combination with trametinib/dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. 1. Data on file 2. C. Robert et al.Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. NEJM 2019. 381:626-636 3. https://data.health.gov.il/drugs/alonim/Rishum_13_582770219.pdf 4. https://data.health.gov.il/drugs/alonim/Rishum_13_582765319.pdf

TAFMEK M 4-20 Mar 2020

* Includes both combination and monotherapy; does not include patients on non-commercial programs, such as clinical trials.

Novartis Israel Ltd. 6 Totzeret Haaretz St. Tel Aviv 6744129 Israel , TEL: 03-9201111, FAX: 03-9229331